期刊文献+

阿维A酸治疗银屑病临床疗效观察及血清α-肿瘤坏死因子的检测 被引量:17

The study on TNF-alpha in the sera and the therapeutic effect on psoriasisbefore and after the treatment with neotigason
下载PDF
导出
摘要 目的:观察阿维A酸(新体卡松)治疗前后银屑病患者血清中α-肿瘤坏死因子(TNF-α)水平的变化,初步探讨新体卡松的抗炎及免疫调节机制。方法:采用新体卡松犤0.75mg/(kg·d)犦口服治疗6例严重银屑病,症状缓解后,剂量逐渐减为0.50、0.25mg/(kg·d)服用,维持剂量为10mg/d。治疗前、后分别检测患者血清中TNF-α水平及其生物学活性,并与正常人进行对照。结果:6例患者均达到临床治愈,平均起效时间为(9.83±1.72)d;平均痊愈时间为(105.50±23.08)d;正常人血清TNF-α浓度为(0.55±1.34)pg/mL,生物学活性为(2.22±3.59)%;而银屑病患者治疗前后TNF-α浓度分别为(76.49±42.27)pg/mL、(12.50±7.67)pg/mL,生物学活性分别为(68.82±8.00)%、(20.72±8.94)%;与正常人比较差异均有显著性,未发现严重不良反应。结论:新体卡松治疗严重银屑病患者的效果较好,可能是通过抑制TNF-α的形成而起到抗炎及免疫调节作用。 Objectives: To observe the changes of the level of TNF-alpha in the sera of the patients with psoriasis before and after the treatment with neotigason, and to discuss the anti-inflammatory and immunomodulatory mechanism of the drug. Methods: Six severely illed patients with psoriasis were treated with 0.75 mg/(kg·d) of neotigason at the beginning, then gradually decreased to 0.50 mg/(kg·d) and 0.25 mg/(kg·d) after the symptoms were improved, and the maintenance dose was 10 mg per day. The levels and bioactivity of TNF-alpha in the sera were evaluated before and after the treatment. Also, we compared these data of the patients with those of the normal volunteers. Results: All the 6 patients were clinically cured,the average duration of the patients to respond was (9.83±1.72) days, and the average duration of clinical cure was (105.50±23.08) days. The levels and bioactivity of TNF-alpha in the sera of the normal volunteers were (0.55±1.34)pg/mL and(2.22±3.59)%,respectively.In contrast, the levels and bioactivity of TNF-alpha in the sera of the patients were(76.49±42.27)pg/mL and 68.82±8.00)%, respectively before treatment, and (12.50±7.67)pg/mL and (20.72±8.94)% respectively after treatment. There were significant diferences between the patients and volunteers, and between the patients before and after treatment. No severe side-effects were found in all the 6 patients. Conclusions: The treatment of severe psoriasis with neotigason revealed good therapeutic effect, and neotigason may have anti-inflammatory and immunomodulatory action via the inhibition of TNF-alpha expression.
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2004年第5期278-280,共3页 Journal of Clinical Dermatology
关键词 银屑病 阿维A酸α-肿瘤坏死因子 psoriasis neotigason tumor necrosis factor-α
  • 相关文献

参考文献9

  • 1Mussi A,Bonifati C,Carducci M,et al.Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis [J].J Biol Regul Homeost Agents,1997,11(3): 115-118.
  • 2Chodorowska G.Plasma concentrations of IFN-gamma and TNFalpha in psoriatic patients before and after local treatment with dithranol ointment[J].J Eur Acad Dermatol Venereol,1998,10(2): 147-151.
  • 3Gottlieb AB.Infliximab for psoriasis[J].J Am Acad Dermatol,2003,49(2 Suppl): S112-S117.
  • 4Chaudhari U,Romano P,Mulcahy LD,et al.Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial[J].Lancet,2001,357(9271): 1842-1847.
  • 5Pfundt R,Wingens M,Bergers M,et al.TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway [J].Arch Dermatol Res,2000,292(4): 180-187.
  • 6Fransson J,de la Torre B,Hammar H.Psoriatic fibroblasts secrete lower amounts of IL-6 than healthy fibroblasts before and after stimulation with TNF-alpha[J].Arch Dermatol Res,1999,291(10): 538-541.
  • 7Trefzer U,Brockhaus M,Loetscher H,et al.55-kd tumor necrosis factor receptor is expressed by human keratinocytes and plays a pivotal role in regulation of human keratinocyte ICAM-1expression[J].J Invest Dermatol,1991,97(5): 911-916.
  • 8Becherel PA,Le Goif L,Ktorza S,et al.CD23-mediated nitric oxide synthase pathway induction in human keratinocytes is inhibited by retinoic acid derivatives[J].J Invest Dermatol,1996,106(6): 1182-1186.
  • 9Motomura K,Ohata M,Satre M,et al.Destabilization of TNFalpha mRNA by retinoic acid in hepatic macrophages:implications for alcoholic liver disease [J].Am J Physiol Endocrinol Metab,2001,281(3): E420-E429.

同被引文献115

引证文献17

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部